Home | All trials

[RDF data]
Trial NCT00000347

Resource URI: http://static.linkedct.org/resource/trials/NCT00000347
PropertyValue
linkedct:brief_title Risperidone for Treatment of Cocaine Dependence in Outpatients - 12
linkedct:condition <http://static.linkedct.org/resource/condition/2992>
linkedct:criteria Inclusion Criteria: M/F ages 21-50 . Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent. Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 50 Years
linkedct:eligibility_minimum_age 21 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date September 20, 1999
linkedct:id NCT00000347
rdfs:label Trial NCT00000347
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Institute on Drug Abuse (NIDA)
linkedct:location <http://static.linkedct.org/resource/location/209856>
linkedct:nct_id NCT00000347
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Risperidone for Treatment of Cocaine Dependence in Outpatients
linkedct:org_study_id NIDA-3-0010-12
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/60742>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000347>
linkedct:phase Phase 2
linkedct:secondary_id Y01-3-0010-12
linkedct:source National Institute on Drug Abuse (NIDA)
linkedct:start_date July 1997
linkedct:study_design Treatment, Double-Blind, Placebo Control, Parallel Assignment
linkedct:study_type Interventional
linkedct:summary The purpose of this study is to evaluate pharmacological efficacy and clinical safety of risperidone in the treatment of cocaine and amphetamine dependence.
rdf:type linkedct:trials
linkedct:verification_date March 1998